Predict your next investment

HEALTHCARE | Biotechnology

See what CB Insights has to offer

Founded Year



Growth Equity | Dead

Total Raised


Last Raised


About Cryopharm

Company was originally focusing on cryopreservation; however, that technology was sold to Gambro GmbH in August 1993 for $4.6MM plus royalties. Cryopharm is now focused on the development of technologies to assure the safe transfusion of blood and blood products for the treatment of life-threatening diseases and emergency medical situations. The company has developed and tested a proprietary technique for the cost-effective viral inactivation of commercially valuable biological cells and human or animal-derived blood plasma products. The core technology is based on novel, light-activated, antiviral compounds, derived from psoralens that destroy potentially harmful blood-borne viruses that can harbor in blood samples. The goal is to use these psoralen derivatives to reduce the contamination of blood supplies worldwide. S.G. Warburg is raising $15MM for the company. Contact Jane Pritchett at (212) 783-7297 for offering memorandum.

Cryopharm Headquarter Location

2585 Nina Street

Pasadena, California, 91107,

United States


Latest Cryopharm News

NeutriSci Provides Corporate Update on Contract Partner, New Markets and Product Line

Aug 31, 2020

VANCOUVER, BC / ACCESSWIRE / August 31, 2020 / NeutriSci International Inc. (“NeutriSci” or the “Company”) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), an innovative technology company developing products for the nutraceutical industry, in conjunction with its manufacturing partner, Cryopharm, is pleased to announce new market entrance and the details of the release of new product lines in October 2020. The existing Cryopharm product line consisting of Marbl melts will now be complemented by Kali Juice. Kali Juice is a delicious cannabis-infused drink mix with zero sugar and zero calories. It comes in three different flavors – Pink Lemonade, Raspberry Punch and Sweet Iced Tea. All brands use the NeutriSci IP and technology as well as its proprietary ingredients to produce the products. The product lines, including Kushtabs and Zenstix, are planned for immediate launch in California with another Western state to be released next month and will have access to 600 dispensaries in the state. The Company would also like to clarify that pursuant to its revenue recognition policy, the revenue received from the initial sample order for Japan will be recognized in the Q3 quarterly report. Revenues are recognized when the Company satisfies its performance obligation by transferring control of its product to a customer. Control is considered to be transferred at the time the customer receives the product. After the previously announced news related to the project in Japan, receipt of the 7-tablet final working samples for the Japan project are approximately 10-15 days off schedule. This is due in large part to reduced production hours in Asia, as well as slower than anticipated shipping times because of current COVID conditions in the region. Approvals of the final packaging by Tabletz LLC. are expected to be completed during the next two weeks. Glen Rehman, CEO of NeutriSci, stated: “We have encountered a delay in receiving the final version of working samples for the 7-tablet packaging for the Japan project. Production of the final version has been completed and has been shipped for final approval. We anticipate the final step to be completed in the next two weeks followed by the first initial order. We are looking forward to the launch of the Tabletz website as well as providing more details regarding the distribution network in Japan. Additionally, the progress that Cryopharm is making entering new markets presents a positive outlook for us.” “I also want our investors to know and understand that we are doing our very best to complete the tasks related to Japan, California and beyond in a timely fashion because we are fully aware that during these times, we are going to be subject to lost time due to things beyond our control. Everyone is aware that these are difficult times and while we will experience challenges along the way, we will be successful in our endeavours”, he added. About NeutriSci International Inc. NeutriSci specializes in the innovation, production, and formulation of nutraceutical products. Established in 2009, NeutriSci’s is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for neuenergy®, the Company’s natural energy and focus supplement that has at its core, the beneficial effects of blueberries. For more information, please visit: . On Behalf of the Board of Directors of NEUTRISCI INTERNATIONAL INC. For investor inquiries, please contact [email protected] Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward-looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure, or prevent any disease. SOURCE: NeutriSci International Inc.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.